The Experts below are selected from a list of 309 Experts worldwide ranked by ideXlab platform
Michiaki Mishima - One of the best experts on this subject based on the ideXlab platform.
-
cerebrospinal Fluid Concentration of gefitinib and erlotinib in patients with non small cell lung cancer
Cancer Chemotherapy and Pharmacology, 2012Co-Authors: Yosuke Togashi, Katsuhiro Masago, Satohiro Masuda, Tomoyuki Mizuno, Masahide Fukudo, Yasuaki Ikemi, Yuichi Sakamori, Hiroki Nagai, Toshiya Katsura, Michiaki MishimaAbstract:Several cases have been reported in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. However, there has been no study in which cerebrospinal Fluid (CSF) Concentrations of gefitinib and erlotinib are directly compared. Thus, we aimed to compare them. We examined 15 Japanese patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib). Plasma and CSF Concentrations were determined using high-performance liquid chromatography with tandem mass spectrometry. The Concentration and penetration rate of gefitinib (mean ± standard deviation) in the CSF were 3.7 ± 1.9 ng/mL (8.2 ± 4.3 nM) and 1.13 ± 0.36 %, respectively. The Concentration and penetration rate of erlotinib in the CSF were 28.7 ± 16.8 ng/mL (66.9 ± 39.0 nM) and 2.77 ± 0.45 %, respectively. The CSF Concentration and penetration rate of erlotinib were significantly higher than those of gefitinib (P = 0.0008 and <0.0001, respectively). The CNS response rates of patients with erlotinib treatment were preferentially (but not significantly) higher than those with gefitinib treatment. (1/3 vs. 4/7, respectively). Leptomeningeal metastases in one patient, which were refractory to gefitinib, dramatically responded to erlotinib. This study suggested that higher CSF Concentration could be achieved with erlotinib and that erlotinib could be more effective for the treatment for CNS metastases, especially leptomeningeal metastases, than gefitinib.
-
cerebrospinal Fluid Concentration of erlotinib and its active metabolite osi 420 in patients with central nervous system metastases of non small cell lung cancer
Journal of Thoracic Oncology, 2010Co-Authors: Yosuke Togashi, Katsuhiro Masago, Masahide Fukudo, Yuichi Sakamori, Tomohiro Terada, Shiro Fujita, Kaoru Irisa, Kenichi Inui, Michiaki MishimaAbstract:Background Although there have been several reports in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) were improved by erlotinib, cerebrospinal Fluid (CSF) penetration of erlotinib in such patients has not been reported. We investigated CSF Concentrations of erlotinib and its active metabolite OSI-420. Method We administered 150 mg erlotinib daily to four patients with NSCLC who had CNS metastases, and we investigated plasma pharmacokinetics of erlotinib and OSI-420 on days 1 and 8. In addition, we measured the Concentrations of erlotinib and OSI-420 in CSF just before administration of erlotinib on day 8. Results In all cases except for one case, plasma pharmacokinetics data on day 8 were similar to those previously reported. The mean ± SD CSF Concentrations of erlotinib and OSI-420 were 54 ± 30 ng/ml and 10.8 ± 8.2 ng/ml, respectively. The mean ± SD CSF penetration rates of erlotinib and OSI-420 were 5.1% ± 1.9% and 5.8% ± 3.6%, respectively. CSF Concentrations of erlotinib exceeded median inhibitory Concentration (IC 50 ) of erlotinib in intact tumor cells with wild-type epidermal growth factor receptor gene. Conclusion The CSF penetrations of erlotinib and OSI-420 in patients with NSCLC who had CNS metastases were approximately 5.1% and 5.8%, respectively. This indicates that erlotinib can become a treatment option for CNS metastases of NSCLC.
Yosuke Togashi - One of the best experts on this subject based on the ideXlab platform.
-
cerebrospinal Fluid Concentration of gefitinib and erlotinib in patients with non small cell lung cancer
Cancer Chemotherapy and Pharmacology, 2012Co-Authors: Yosuke Togashi, Katsuhiro Masago, Satohiro Masuda, Tomoyuki Mizuno, Masahide Fukudo, Yasuaki Ikemi, Yuichi Sakamori, Hiroki Nagai, Toshiya Katsura, Michiaki MishimaAbstract:Several cases have been reported in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. However, there has been no study in which cerebrospinal Fluid (CSF) Concentrations of gefitinib and erlotinib are directly compared. Thus, we aimed to compare them. We examined 15 Japanese patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib). Plasma and CSF Concentrations were determined using high-performance liquid chromatography with tandem mass spectrometry. The Concentration and penetration rate of gefitinib (mean ± standard deviation) in the CSF were 3.7 ± 1.9 ng/mL (8.2 ± 4.3 nM) and 1.13 ± 0.36 %, respectively. The Concentration and penetration rate of erlotinib in the CSF were 28.7 ± 16.8 ng/mL (66.9 ± 39.0 nM) and 2.77 ± 0.45 %, respectively. The CSF Concentration and penetration rate of erlotinib were significantly higher than those of gefitinib (P = 0.0008 and <0.0001, respectively). The CNS response rates of patients with erlotinib treatment were preferentially (but not significantly) higher than those with gefitinib treatment. (1/3 vs. 4/7, respectively). Leptomeningeal metastases in one patient, which were refractory to gefitinib, dramatically responded to erlotinib. This study suggested that higher CSF Concentration could be achieved with erlotinib and that erlotinib could be more effective for the treatment for CNS metastases, especially leptomeningeal metastases, than gefitinib.
-
cerebrospinal Fluid Concentration of erlotinib and its active metabolite osi 420 in patients with central nervous system metastases of non small cell lung cancer
Journal of Thoracic Oncology, 2010Co-Authors: Yosuke Togashi, Katsuhiro Masago, Masahide Fukudo, Yuichi Sakamori, Tomohiro Terada, Shiro Fujita, Kaoru Irisa, Kenichi Inui, Michiaki MishimaAbstract:Background Although there have been several reports in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) were improved by erlotinib, cerebrospinal Fluid (CSF) penetration of erlotinib in such patients has not been reported. We investigated CSF Concentrations of erlotinib and its active metabolite OSI-420. Method We administered 150 mg erlotinib daily to four patients with NSCLC who had CNS metastases, and we investigated plasma pharmacokinetics of erlotinib and OSI-420 on days 1 and 8. In addition, we measured the Concentrations of erlotinib and OSI-420 in CSF just before administration of erlotinib on day 8. Results In all cases except for one case, plasma pharmacokinetics data on day 8 were similar to those previously reported. The mean ± SD CSF Concentrations of erlotinib and OSI-420 were 54 ± 30 ng/ml and 10.8 ± 8.2 ng/ml, respectively. The mean ± SD CSF penetration rates of erlotinib and OSI-420 were 5.1% ± 1.9% and 5.8% ± 3.6%, respectively. CSF Concentrations of erlotinib exceeded median inhibitory Concentration (IC 50 ) of erlotinib in intact tumor cells with wild-type epidermal growth factor receptor gene. Conclusion The CSF penetrations of erlotinib and OSI-420 in patients with NSCLC who had CNS metastases were approximately 5.1% and 5.8%, respectively. This indicates that erlotinib can become a treatment option for CNS metastases of NSCLC.
Katsuhiro Masago - One of the best experts on this subject based on the ideXlab platform.
-
cerebrospinal Fluid Concentration of gefitinib and erlotinib in patients with non small cell lung cancer
Cancer Chemotherapy and Pharmacology, 2012Co-Authors: Yosuke Togashi, Katsuhiro Masago, Satohiro Masuda, Tomoyuki Mizuno, Masahide Fukudo, Yasuaki Ikemi, Yuichi Sakamori, Hiroki Nagai, Toshiya Katsura, Michiaki MishimaAbstract:Several cases have been reported in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. However, there has been no study in which cerebrospinal Fluid (CSF) Concentrations of gefitinib and erlotinib are directly compared. Thus, we aimed to compare them. We examined 15 Japanese patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib). Plasma and CSF Concentrations were determined using high-performance liquid chromatography with tandem mass spectrometry. The Concentration and penetration rate of gefitinib (mean ± standard deviation) in the CSF were 3.7 ± 1.9 ng/mL (8.2 ± 4.3 nM) and 1.13 ± 0.36 %, respectively. The Concentration and penetration rate of erlotinib in the CSF were 28.7 ± 16.8 ng/mL (66.9 ± 39.0 nM) and 2.77 ± 0.45 %, respectively. The CSF Concentration and penetration rate of erlotinib were significantly higher than those of gefitinib (P = 0.0008 and <0.0001, respectively). The CNS response rates of patients with erlotinib treatment were preferentially (but not significantly) higher than those with gefitinib treatment. (1/3 vs. 4/7, respectively). Leptomeningeal metastases in one patient, which were refractory to gefitinib, dramatically responded to erlotinib. This study suggested that higher CSF Concentration could be achieved with erlotinib and that erlotinib could be more effective for the treatment for CNS metastases, especially leptomeningeal metastases, than gefitinib.
-
cerebrospinal Fluid Concentration of erlotinib and its active metabolite osi 420 in patients with central nervous system metastases of non small cell lung cancer
Journal of Thoracic Oncology, 2010Co-Authors: Yosuke Togashi, Katsuhiro Masago, Masahide Fukudo, Yuichi Sakamori, Tomohiro Terada, Shiro Fujita, Kaoru Irisa, Kenichi Inui, Michiaki MishimaAbstract:Background Although there have been several reports in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) were improved by erlotinib, cerebrospinal Fluid (CSF) penetration of erlotinib in such patients has not been reported. We investigated CSF Concentrations of erlotinib and its active metabolite OSI-420. Method We administered 150 mg erlotinib daily to four patients with NSCLC who had CNS metastases, and we investigated plasma pharmacokinetics of erlotinib and OSI-420 on days 1 and 8. In addition, we measured the Concentrations of erlotinib and OSI-420 in CSF just before administration of erlotinib on day 8. Results In all cases except for one case, plasma pharmacokinetics data on day 8 were similar to those previously reported. The mean ± SD CSF Concentrations of erlotinib and OSI-420 were 54 ± 30 ng/ml and 10.8 ± 8.2 ng/ml, respectively. The mean ± SD CSF penetration rates of erlotinib and OSI-420 were 5.1% ± 1.9% and 5.8% ± 3.6%, respectively. CSF Concentrations of erlotinib exceeded median inhibitory Concentration (IC 50 ) of erlotinib in intact tumor cells with wild-type epidermal growth factor receptor gene. Conclusion The CSF penetrations of erlotinib and OSI-420 in patients with NSCLC who had CNS metastases were approximately 5.1% and 5.8%, respectively. This indicates that erlotinib can become a treatment option for CNS metastases of NSCLC.
Yuichi Sakamori - One of the best experts on this subject based on the ideXlab platform.
-
cerebrospinal Fluid Concentration of gefitinib and erlotinib in patients with non small cell lung cancer
Cancer Chemotherapy and Pharmacology, 2012Co-Authors: Yosuke Togashi, Katsuhiro Masago, Satohiro Masuda, Tomoyuki Mizuno, Masahide Fukudo, Yasuaki Ikemi, Yuichi Sakamori, Hiroki Nagai, Toshiya Katsura, Michiaki MishimaAbstract:Several cases have been reported in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. However, there has been no study in which cerebrospinal Fluid (CSF) Concentrations of gefitinib and erlotinib are directly compared. Thus, we aimed to compare them. We examined 15 Japanese patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib). Plasma and CSF Concentrations were determined using high-performance liquid chromatography with tandem mass spectrometry. The Concentration and penetration rate of gefitinib (mean ± standard deviation) in the CSF were 3.7 ± 1.9 ng/mL (8.2 ± 4.3 nM) and 1.13 ± 0.36 %, respectively. The Concentration and penetration rate of erlotinib in the CSF were 28.7 ± 16.8 ng/mL (66.9 ± 39.0 nM) and 2.77 ± 0.45 %, respectively. The CSF Concentration and penetration rate of erlotinib were significantly higher than those of gefitinib (P = 0.0008 and <0.0001, respectively). The CNS response rates of patients with erlotinib treatment were preferentially (but not significantly) higher than those with gefitinib treatment. (1/3 vs. 4/7, respectively). Leptomeningeal metastases in one patient, which were refractory to gefitinib, dramatically responded to erlotinib. This study suggested that higher CSF Concentration could be achieved with erlotinib and that erlotinib could be more effective for the treatment for CNS metastases, especially leptomeningeal metastases, than gefitinib.
-
cerebrospinal Fluid Concentration of erlotinib and its active metabolite osi 420 in patients with central nervous system metastases of non small cell lung cancer
Journal of Thoracic Oncology, 2010Co-Authors: Yosuke Togashi, Katsuhiro Masago, Masahide Fukudo, Yuichi Sakamori, Tomohiro Terada, Shiro Fujita, Kaoru Irisa, Kenichi Inui, Michiaki MishimaAbstract:Background Although there have been several reports in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) were improved by erlotinib, cerebrospinal Fluid (CSF) penetration of erlotinib in such patients has not been reported. We investigated CSF Concentrations of erlotinib and its active metabolite OSI-420. Method We administered 150 mg erlotinib daily to four patients with NSCLC who had CNS metastases, and we investigated plasma pharmacokinetics of erlotinib and OSI-420 on days 1 and 8. In addition, we measured the Concentrations of erlotinib and OSI-420 in CSF just before administration of erlotinib on day 8. Results In all cases except for one case, plasma pharmacokinetics data on day 8 were similar to those previously reported. The mean ± SD CSF Concentrations of erlotinib and OSI-420 were 54 ± 30 ng/ml and 10.8 ± 8.2 ng/ml, respectively. The mean ± SD CSF penetration rates of erlotinib and OSI-420 were 5.1% ± 1.9% and 5.8% ± 3.6%, respectively. CSF Concentrations of erlotinib exceeded median inhibitory Concentration (IC 50 ) of erlotinib in intact tumor cells with wild-type epidermal growth factor receptor gene. Conclusion The CSF penetrations of erlotinib and OSI-420 in patients with NSCLC who had CNS metastases were approximately 5.1% and 5.8%, respectively. This indicates that erlotinib can become a treatment option for CNS metastases of NSCLC.
Masahide Fukudo - One of the best experts on this subject based on the ideXlab platform.
-
cerebrospinal Fluid Concentration of gefitinib and erlotinib in patients with non small cell lung cancer
Cancer Chemotherapy and Pharmacology, 2012Co-Authors: Yosuke Togashi, Katsuhiro Masago, Satohiro Masuda, Tomoyuki Mizuno, Masahide Fukudo, Yasuaki Ikemi, Yuichi Sakamori, Hiroki Nagai, Toshiya Katsura, Michiaki MishimaAbstract:Several cases have been reported in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. However, there has been no study in which cerebrospinal Fluid (CSF) Concentrations of gefitinib and erlotinib are directly compared. Thus, we aimed to compare them. We examined 15 Japanese patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib). Plasma and CSF Concentrations were determined using high-performance liquid chromatography with tandem mass spectrometry. The Concentration and penetration rate of gefitinib (mean ± standard deviation) in the CSF were 3.7 ± 1.9 ng/mL (8.2 ± 4.3 nM) and 1.13 ± 0.36 %, respectively. The Concentration and penetration rate of erlotinib in the CSF were 28.7 ± 16.8 ng/mL (66.9 ± 39.0 nM) and 2.77 ± 0.45 %, respectively. The CSF Concentration and penetration rate of erlotinib were significantly higher than those of gefitinib (P = 0.0008 and <0.0001, respectively). The CNS response rates of patients with erlotinib treatment were preferentially (but not significantly) higher than those with gefitinib treatment. (1/3 vs. 4/7, respectively). Leptomeningeal metastases in one patient, which were refractory to gefitinib, dramatically responded to erlotinib. This study suggested that higher CSF Concentration could be achieved with erlotinib and that erlotinib could be more effective for the treatment for CNS metastases, especially leptomeningeal metastases, than gefitinib.
-
cerebrospinal Fluid Concentration of erlotinib and its active metabolite osi 420 in patients with central nervous system metastases of non small cell lung cancer
Journal of Thoracic Oncology, 2010Co-Authors: Yosuke Togashi, Katsuhiro Masago, Masahide Fukudo, Yuichi Sakamori, Tomohiro Terada, Shiro Fujita, Kaoru Irisa, Kenichi Inui, Michiaki MishimaAbstract:Background Although there have been several reports in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) were improved by erlotinib, cerebrospinal Fluid (CSF) penetration of erlotinib in such patients has not been reported. We investigated CSF Concentrations of erlotinib and its active metabolite OSI-420. Method We administered 150 mg erlotinib daily to four patients with NSCLC who had CNS metastases, and we investigated plasma pharmacokinetics of erlotinib and OSI-420 on days 1 and 8. In addition, we measured the Concentrations of erlotinib and OSI-420 in CSF just before administration of erlotinib on day 8. Results In all cases except for one case, plasma pharmacokinetics data on day 8 were similar to those previously reported. The mean ± SD CSF Concentrations of erlotinib and OSI-420 were 54 ± 30 ng/ml and 10.8 ± 8.2 ng/ml, respectively. The mean ± SD CSF penetration rates of erlotinib and OSI-420 were 5.1% ± 1.9% and 5.8% ± 3.6%, respectively. CSF Concentrations of erlotinib exceeded median inhibitory Concentration (IC 50 ) of erlotinib in intact tumor cells with wild-type epidermal growth factor receptor gene. Conclusion The CSF penetrations of erlotinib and OSI-420 in patients with NSCLC who had CNS metastases were approximately 5.1% and 5.8%, respectively. This indicates that erlotinib can become a treatment option for CNS metastases of NSCLC.